Pathogen‐reduced platelets in pediatric and neonatal patients: Demographics, transfusion rates, and transfusion reactions. Issue 10 (27th August 2021)

• Record Type: Journal Article
• Authors: Lasky, Baia; Nolasco, Joseph; Graff, Jazmin; Ward, Dawn C.; Ziman, Alyssa; McGonigle, Andrea M.
• Is Part Of: Transfusion. Volume 61:Issue 10(2021)
• Page Start: 2869
• Page End: 2876
• Publication Date: 2021-08-27
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16639
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: Pathogen‐reduced platelets (PR PLT) are the emerging standard for proactive transfusion‐transmitted infection (TTI) mitigation. There is, however, continued hesitation to transfuse PR PLT in children due to limited published data. We report demographics, rates of transfusion, and transfusion reactions (TR) associated with FDA‐approved PR PLT in pediatric and neonatal patients at an academic medical center. Methods: Retrospective review was performed for patients <18 years receiving at least one platelet over a 300‐day period at a large, tertiary care hospital. Patients were transfused PR or conventional (CONV) PLT, based on inventory availability. Statistical analysis was performed using Fisher Exact Test. Results: During the study period, 191 patients received 1010 platelet transfusions (892 units). Sixty‐eight patients received PR PLT only (1.3 units/patient, 95% confidence interval [CI] 1.1–1.5; 1.8 transfusions/patient, 95% CI 1.4–2.2), and 56 patients received CONV PLT only (1.4 units/patient, 95% CI 1.1–1.7; 1.6 transfusions/patient, 95% CI 1.3–1.9). Patients with hematologic malignancies undergoing chemotherapy/radiation and allogeneic hematopoietic stem cell transplant received the most platelet transfusions and more commonly received both platelet types. Of 506 PR PLT units, 5 TRs occurred; 386 CONV PLT resulted in two TRs ( p = .7052). Of 51 neonates, 37 received PR PLT without adverse events, including 13 receiving phototherapy. No TTIs were identified in any group. Conclusion: There was no significant difference in rates of transfusion or TRs between PR and CONV PLT. Our study provides additional evidence that PR PLT can be transfused to pediatric and neonatal patients without increasing the risk of acute adverse events.